161715-27-1

Basic information

• Product Name: 3-Hydroxy-1-(1,3-thiazolin-2-yl)azetidine
• Synonyms: 3-Hydroxy-1-(1,3-thiazolin-2-yl)azetidine;1-(4,5-Dihydrothiazol-2-yl)azetidin-3-ol;1-(4,5-dihydro-2-thiazolyl)-3-Azetidinol
• CAS NO: 161715-27-1
• Molecular Formula: C₆H₁₀N₂OS
• Molecular Weight: 158.2214
• EINECS: -0
• Product Categories: API
• Mol File: 161715-27-1.mol

Chemical Properties

• Melting Point: 114-117℃
• Boiling Point: 306.812 °C at 760 mmHg
• Flash Point: 139.355 °C
• Appearance: /
• Density: 1.59
• Storage Temp.: 2-8°C
• PKA: 13.70±0.20(Predicted)
• CAS DataBase Reference: 3-Hydroxy-1-(1,3-thiazolin-2-yl)azetidine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Hydroxy-1-(1,3-thiazolin-2-yl)azetidine(161715-27-1)
• EPA Substance Registry System: 3-Hydroxy-1-(1,3-thiazolin-2-yl)azetidine(161715-27-1)

Safety Data

• Hazardous Substances Data: 161715-27-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Hydroxy-1-(1,3-thiazolin-2-yl)azetidine is used as a potential therapeutic agent for various medical conditions due to its potential anti-tumor, anti-inflammatory, and antimicrobial activities. Its unique structure and the presence of a hydroxy group may contribute to its enhanced pharmacological properties, making it a candidate for drug discovery and development.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 3-Hydroxy-1-(1,3-thiazolin-2-yl)azetidine serves as a subject of study for its potential to be modified and optimized for specific therapeutic applications. Its thiazoline core and hydroxyl functionality offer opportunities for the design of new drugs with improved efficacy and selectivity.
Further research is necessary to fully explore the potential applications and therapeutic benefits of 3-Hydroxy-1-(1,3-thiazolin-2-yl)azetidine across different medical and scientific domains.

Upstream product

• 19975-56-5 2-methylsulfanyl-4,5-dihydrothiazoline 
• 18621-18-6 azetion-3-ol hydrochloride 

Downstream Products

• 161715-24-8 tebipenem 
• 161715-20-4 (+)-(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-{[1-(2-thiazolin-2-yl)-3-azetidinyl]sulfanyl}-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid-p-nitrobenzyl ester 
• 161715-28-2 3-acetylthio-1-(1,3-thiazolin-2-yl)azetidine 
• 161715-21-5 Tebipenem 

Relevant articles and documents

Syntheses and pharmacokinetic studies of prodrug esters for the development of oral carbapenem, L-084

We discovered an orally active carbapenem, L-084, through pharmacokinetic studies on various prodrug esters of (1R,5S,6S)-6-[(R)-1-hydroxyethyl]-1-methyl- 2-[1-(1,3-thiazolin-2-yl)azetidin-3-yl]thio-1-carbapen-2-em-3-carboxylic acid (LJC11,036). L-084 showed a strong antimicrobial activity against Gram-positive and Gram-negative bacteria and exhibited the highest intestinal absorption among synthesized prodrugs of LJC11,036. Japan Antibiotics Research Association.

Carbapenem-3-carboxylic acid ester derivatives

Disclosed are carbapenem-3-carboxylic acid ester derivatives of formula (I), wherein R1 is a hydrogen atom or a lower alkyl group, R2 is an alkyl group which may be substituted by a cycloalkyl group having about 4 to 7 carbon atoms and which may be substituted by a lower alkyl group, or is a cycloalkyl group having 4 to 7 carbon atoms which may be substituted by a lower alkyl group and n is 0 or 1. The compounds are highly absorbable through the digestive tract and are rapidly converted in the body to the active compound, which shows strong antibacterial activity. STR1